KPV (gut use)

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone and retains most of its anti-inflammatory activity while losing melanocortin receptor pigmentation and appetite effects. In colonic epithelium and macrophages it is taken up by the PepT1 di/tripeptide transporter — which is notably upregulated in inflamed intestine — and then inhibits NF-kB nuclear translocation and p38 MAPK signalling, reducing IL-6, IL-8 and TNF-alpha production. In DSS and TNBS colitis models this translates into less weight loss, lower histological damage scores and reduced myeloperoxidase. Because PepT1 expression rises in inflamed tissue, the peptide preferentially concentrates where the inflammation is, which is the most interesting thing about it.

Targets: NF-kB pathway, PepT1 transporter, p38 MAPK, IL-6 / IL-8 / TNF-alpha

• · Enteric-coated capsules are preferred by people targeting the colon specifically, so more peptide survives to the distal bowel. Reconstituted peptide swallowed directly is the cheaper and more common approach.
• · Used when the goal is systemic or skin/mast-cell inflammation rather than luminal gut disease.

Work out your exact syringe units →

• commonInjection-site redness or itch (subcutaneous route)— Transient.
• uncommonMild nausea after oral dosing— Usually resolves with continued use.
• uncommonHeadache
• uncommonUnknown long-term immune consequences— It is an immunosuppressive signal; blunting NF-kB indefinitely has never been studied in humans with this molecule.

• Active untreated infection — suppressing NF-kB blunts a defence you may need.
• Do not use it as monotherapy in place of proven IBD therapy during a flare; there is no evidence it controls moderate-to-severe disease.

• synergybpc-157-gut — The default oral gut stack — KPV for inflammation, BPC-157 for mucosal repair.
• cautionimmunosuppressants — Additive immune suppression on top of biologics or thiopurines is untested.

• · Faecal calprotectin is the single most useful objective marker if you are using this for IBD.
• · CRP and symptom diaries alongside whatever your gastroenterologist already tracks.

Not approved for human use. Sold as a research chemical; also appears in cosmetic topicals where the regulatory position is different.

• Dalmasso et al. 2008, PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation, Gastroenterology (preclinical)
• Xiao et al., nanoparticle-delivered KPV in colitis models (preclinical)
• Brzoska et al., alpha-MSH and derived peptides in inflammatory disease (review)

KPV is the smallest fragment of alpha-MSH that retains most of the parent hormone's anti-inflammatory activity, and it does so without the melanocortin receptor engagement responsible for pigmentation, appetite suppression and the sexual effects of the larger melanocortin peptides. That dissociation is the whole reason the fragment is interesting: you get the NF-kB effect without becoming a tanning peptide. The delivery mechanism is the elegant part. PepT1 (SLC15A1) is a proton-coupled oligopeptide transporter normally expressed in small intestine and essentially absent from healthy colon. In inflamed colonic epithelium it is upregulated, and it is also expressed on activated macrophages. So a PepT1 substrate delivered to an inflamed bowel concentrates preferentially in exactly the cells driving the inflammation. That is target enrichment by disease state, which very few drugs achieve. Once inside, KPV suppresses NF-kB nuclear translocation and blunts p38 MAPK signalling, cutting IL-6, IL-8 and TNF-alpha output. In DSS and TNBS colitis models this shows up as less weight loss, lower histological damage scores, and reduced myeloperoxidase — the standard trio. Later nanoparticle work loaded KPV into PepT1-targeted particles and reported efficacy at doses orders of magnitude below free peptide, which is a strong argument that free oral peptide is a poor delivery vehicle. What is missing is the human half. There has never been a completed clinical trial of KPV in inflammatory bowel disease. Everything above is rodent and cell-culture work, and the leap from 'suppresses NF-kB in a mouse colon' to 'controls your ulcerative colitis' is exactly the leap that has killed dozens of IBD drug programmes.

The main thing that goes wrong is that KPV works well enough symptomatically to let somebody with real inflammatory bowel disease drift off proper therapy. Reduced urgency and less bloating feel like remission. Endoscopic and histological remission is a different thing, and the gap between them is where strictures, fistulas and dysplasia develop quietly. This is the specific reason calprotectin is non-negotiable if you have diagnosed IBD. Second: delivery mismatch. Most people swallow reconstituted KPV solution and expect a colonic effect. A three-residue peptide with no protection is absorbed or hydrolysed well before the colon. If your disease is distal, uncoated oral dosing is probably delivering the peptide to the wrong segment, and the rodent data that motivated you used direct or targeted delivery. Third: indefinite use. The rodent studies run days to weeks. People run KPV continuously for a year because it is 'just a tripeptide'. It is a tripeptide that suppresses a master immune transcription factor, and the long-term human consequence of that is genuinely unknown. Fourth, minor but common: the early nausea after oral dosing gets treated as intolerance and people quit at day three. It usually resolves within a week, and taking it with a small amount of water rather than dry fixes most of it.

1. 250 mcgWeek 1 — 250 mcg once daily orally, empty stomach. Purely to establish tolerance — the early nausea is the only common issue and it usually settles.
2. 500 mcgWeeks 2-8 — 250 mcg twice daily, or 500 mcg once daily. This is where nearly every protocol sits. There is no human dose-ranging data, so this number is community consensus rather than pharmacology.
3. 500 mcgWeeks 2-8, distal disease — If your disease is colonic rather than small-bowel, an enteric-coated capsule at the same dose is a more rational delivery choice than swallowing reconstituted solution — an unprotected tripeptide is largely gone before the ileocaecal valve. This is mechanistic reasoning, not trial evidence.
4. —Week 8 onward — Reassess against calprotectin. Stop for four weeks, or continue on evidence rather than habit. Indefinite immunosuppression with an unstudied molecule is the actual risk here, and it is a slow one.

• PepT1 / SLC15A1 oligopeptide transporter — Substrate rather than ligand; no Km for KPV specifically that I could resolve.

  Mediates uptake into colonic epithelial cells and activated macrophages. Critically, PepT1 is upregulated in inflamed intestine and near-absent in healthy colon, so uptake is disease-enriched. This is the single most interesting pharmacological property of the molecule.

• NF-kB signalling — Intracellular pathway inhibition; no binding constant.

  Reduced IkB degradation and reduced p65 nuclear translocation, cutting transcription of IL-6, IL-8 and TNF-alpha. This is the primary anti-inflammatory output.

• p38 MAPK — No binding constant.

  Blunted phosphorylation, contributing to reduced cytokine production and reduced neutrophil recruitment into the mucosa.

• Melanocortin receptors (MC1R-MC5R) — Very low to negligible. KPV lacks the His-Phe-Arg-Trp core message sequence that confers melanocortin receptor binding.

  Essentially none — and that is the design intent. KPV's anti-inflammatory action is generally held to be melanocortin-receptor-independent, which is why it does not tan you, suppress appetite, or cause the flushing and nausea of the larger melanocortin analogues.

• No completed human trial of KPV in inflammatory bowel disease exists None

  Stated explicitly because it matters. Searches of PubMed and ClinicalTrials.gov in this session surfaced no completed or registered clinical trial of KPV as a gastrointestinal therapeutic. The evidence base is entirely rodent colitis models and cell culture. Anyone presenting KPV as clinically proven for IBD is misrepresenting the literature.

Users typically report changes in urgency, stool consistency and bloating within 7-14 days. Rodent colitis models show histological improvement over 1-3 weeks. Calprotectin, if it is going to move, generally moves over 6-12 weeks — it lags symptoms substantially, which is precisely why it is the useful number. Judge the compound at 12 weeks on the marker, not at 10 days on how you feel.

KPV plus BPC-157 orally is the standard gut stack and the division of labour is coherent: KPV damps the inflammatory signalling, BPC-157 is claimed to drive repair and perfusion. Neither has human gut trial data, so you are stacking two hypotheses. Take both on an empty stomach, separated from food, and give the combination a defined eight-week window with a calprotectin at each end. The interaction that actually needs thought is with real immunosuppression. If you are on a thiopurine, methotrexate, or an anti-TNF or anti-integrin biologic, you are already suppressing overlapping pathways and nobody has studied adding an NF-kB inhibitor on top. The risk is not dramatic and immediate — it is a slow increase in infection risk that you will attribute to the biologic. Do not run KPV through an active infection. Blunting NF-kB is blunting the transcriptional response your innate immune system uses to clear bacteria. Pause it and restart afterwards. KPV also has a legitimate topical and mast-cell-stabilising use separate from the gut case. If you are using it for both, count the total daily dose across routes.

Within this class KPV occupies an unusual position: the mechanism is more specific and better characterised than BPC-157's, and there is independent replication across laboratories, but there is still no human trial. It is better science with the same clinical evidence gap. Against mesalazine, which is the actual first-line luminal anti-inflammatory for mild ulcerative colitis, KPV has no comparative data and mesalazine has decades of it. If you have diagnosed UC and you are choosing between them, that is not a close call. KPV's realistic niche is as an adjunct in someone already on established therapy, or in the large group of people with inflammatory-feeling gut symptoms who do not meet criteria for any diagnosable disease — a population in which nothing has been tested. Against colostrum, colostrum has real human randomised permeability data and a far better safety record; KPV has better mechanistic specificity for inflammation as opposed to barrier function. They target different problems, and that stack is more defensible than either one with BPC-157.

$30–$100/month. Typical grey-market pricing for 10 mg vials at 250-500 mcg/day; roughly one and a half vials a month at the higher dose. Enteric-coated compounded capsules cost substantially more — often two to three times the vial route — and that premium is only worth paying if your target is genuinely distal colonic. Observed market ranges, not verified figures.

• ?No human pharmacokinetic data exist for KPV by any route. Every PK field is null for that reason.
• ?No completed human trial in inflammatory bowel disease exists, which I confirmed by searching rather than assumed.
• ?The Km of KPV at PepT1 is not something I resolved to a number, so 'high capacity transport' is qualitative.
• ?Whether marketed material is the free acid or the C-terminal amide is usually unspecified by vendors, and these are chemically distinct compounds with potentially different stability.
• ?The Xiao et al. PepT1-targeted nanoparticle work referenced in the Core record is real preclinical literature but I did not resolve a specific PMID for it in this session, so it is not cited here.
• ?How much orally administered KPV reaches the distal colon in a human is entirely unknown, and this is the biggest practical gap between the rodent data and the way people actually dose it.
• ?The claim that KPV is melanocortin-receptor-independent is standard in the review literature, but I did not resolve a primary binding study formally excluding MC1R involvement.

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D, Gastroenterology, 2008 · PMID 18061177

  The foundational paper. Establishes that KPV enters colonic epithelium and immune cells via PepT1 and reduces inflammation in DSS and TNBS colitis. Gastroenterology 2008;134:166-78.

• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Kannengiesser K, Maaser C, Heidemann J, et al., Inflammatory Bowel Diseases, 2008 · PMID 18092346

  Independent confirmation from a separate group in murine IBD models — important, because so much of the peptide literature rests on single laboratories.